Novo Nordisk says FDA extends denecimig BLA review amid manufacturing facility remediation

Bitget2026/10/02 20:54

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novo Nordisk’s US BLA review for hemophilia A drug denecimig remains ongoing, with no new FDA decision timeline provided.
Extended review tied to remediation work at a manufacturing facility identified during a pre-license inspection.
FDA flagged no deficiencies in denecimig clinical efficacy or safety data submitted in the application.
2026 financial outlook unchanged; Novo targets a US launch in the first half of 2027, pending FDA action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610021653OMX_____CNEWS_EN_GNW1001276047_en) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novo Nordisk says FDA extends denecimig BLA review amid manufacturing facility remediation

You may also like

Crypto prices